SOLV — Solventum Corp
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1964738 ·
Last close
$89.50
Market Cap
$15.24B
52W High
$94.16
52W Low
$62.38
ADV30
952,897
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,209,000,000 | 1,286,000,000 | 181,000,000 | 92,000,000 | 14,243,000,000 | 403,000,000 | 9,444,000,000 |
| Mar 2026 | 2,006,000,000 | 1,095,000,000 | 79,000,000 | 13,000,000 | 14,097,000,000 | 561,000,000 | 9,127,000,000 |
| Dec 2025 | 1,998,000,000 | 1,027,000,000 | 93,000,000 | 63,000,000 | 14,294,000,000 | 878,000,000 | 9,244,000,000 |
| Sep 2025 | 2,096,000,000 | 1,135,000,000 | 172,000,000 | 1,266,000,000 | 13,973,000,000 | 1,642,000,000 | 8,987,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$207,000,000
Investing CF
$2,857,000,000
Financing CF
$-3,159,000,000
CapEx
$-327,000,000
Dividends Paid
—
Buybacks
$-355,000,000
EPS Diluted TTM
$8.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$1,902,000,000
Inventory
$1,040,000,000
Receivables
$1,432,000,000
ST Investments
—
EBIT TTM
$1,962,000,000
Pretax Income TTM
$1,696,000,000
Interest Exp TTM
$266,000,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,310,000,128
EBITDA
$1,139,000,064
Free Cash Flow
$489,000,000
Enterprise Value
$19,778,064,384
Total Cash
$403,000,000
Total Debt
$5,295,000,064
Shares Out
170,223,729
Trailing EPS
$8.18
Book Value
$28.22
ROE
34.0%
ROA
2.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,325,000,000 | 632,000,000 | 1,556,000,000 | 14,294,000,000 | 9,244,000,000 | 5,050,000,000 | 369,000,000 |
| Dec 2024 | 8,254,000,000 | 1,036,000,000 | 479,000,000 | 14,457,000,000 | 11,498,000,000 | 2,959,000,000 | 1,185,000,000 |
| Dec 2023 | 8,197,000,000 | 1,636,000,000 | 1,346,000,000 | 13,943,000,000 | 2,277,000,000 | 11,666,000,000 | 1,915,000,000 |
| Dec 2022 | 8,130,000,000 | 1,693,000,000 | 1,343,000,000 | 13,594,000,000 | 1,852,000,000 | 11,742,000,000 | 1,679,000,000 |
TTM Snapshot
Revenues TTM
$6,226,000,000
NetIncome TTM
$719,000,000
OpCashFlow TTM
$0
Assets (Latest)
$14,294,000,000
Forward EPS
$7.23
Max Pain — expiry 2026-10-16
max pain strike: $85.00 · spot: $88.82 · call oi: 6,410 · put oi: 1,951
Expected Move to 2026-10-16:
±$5.47
(6.16%) —
implied range
$83.34 –
$94.29
· ATM straddle on $90.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $17.36B | $91.04 | — |
| PEN | Penumbra Inc | $12.56B | $318.89 | — |
| BAX | BAXTER INTERNATIONAL INC | $12.08B | $23.37 | — |
| STE | STERIS plc | $20.37B | $208.93 | — |
| SNN | SMITH & NEPHEW PLC | $11.26B | $26.91 | — |
News headlines (Yahoo Finance, 1h cache)
How Is Solventum's Stock Performance Compared to Other Healthcare Stocks
2026-09-25 10:32 · Yahoo
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
2026-09-17 15:51 · Yahoo
What Solventum (SOLV)'s Earnings Beat and Surgical AI Push Means For Shareholders
2026-09-17 06:12 · Yahoo
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
2026-09-02 20:05 · Yahoo
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
2026-09-02 17:54 · Yahoo
3 Reasons to Avoid SOLV and 1 Stock to Buy Instead
2026-08-28 16:32 · Yahoo
1 Healthcare Stock for Long-Term Investors and 2 Facing Challenges
2026-08-20 12:59 · Yahoo
Are Wall Street Analysts Bullish on Solventum Stock?
2026-08-14 10:07 · Yahoo
Solventum (SOLV) Q2 2026 Earnings Call Transcript
2026-08-13 01:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.